Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 3, 2010, Pages 192-199

  Schmitt, C ^a   Kaeser, B ^a   Riek, M ^a   Bech, N ^b   Kreuzer, C ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Digoxin drug interaction; P glycoprotein; Ritonavir; Saquinavir

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; RITONAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PROTEIN FUNCTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URINALYSIS; VOLUNTEER;

EID: 77949452205     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48192     Document Type: Article

References (25)

1. Arimori K, Nakano M. Drug exsorption from blood into the gastrointestinal tract. Pharm Res. 1998; 15: 371-376.
2. Autar RS, Boffito M, Hassink E, Wit FW, Ananworanich J, Siangphoe U, Pozniak A, Cooper DA, Phanuphak P, Lange JM, Ruxrungtham K, Burger DM. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother. 2005; 56: 908-913.
3. Bittner B, Riek M, Holmes B, Grange S. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther. 2005; 10: 803-810.
4. Bonate PL, Reith K, Weir S. Drug interactions at the renal level - implications for drug development. Clin Pharmacokinet. 1998; 34: 375-404.
5. Deray DG. Ritonavir-induced acute renal failure. Clin Drug Investig. 1998; 16: 175.
6. Ding R, Tayrouz Y, Riedel KD, Burhenne J,Weiss J, MikusG, Haefeli WE. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004; 76: 73-84.
7. Drescher S, Glaeser H, Mürdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003; 73: 223-231.
8. Eagling VA, Back DJ, BarryMG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997; 44: 190-194.
9. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos. 1997; 25: 256-266.
10. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004; 189: 1176-1184.
11. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004; 25: 423-429.
12. Gibaldi M, Perrier D. Non compartmental analysis based on statistical moment theory. In: Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
13. GlaxoSmithKline. Lanoxin® prescribing information, November 2006. Available at: http://us.gsk.com/products/assets/us-lanoxin-tablets.pdf. Accessed September 20, 2008.
14. Hinderling PH, Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit. 1991; 13: 381-401.
15. Kaeser B, Zandt H, Bour F, Zwanziger E, Schmitt C, Zhang X. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimircrob AgentsChemother. 2009; 53: 609-614.
16. Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, Eriksen J, Jakobsen P, Østergaard M, Autrup H, Andersen V. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest. 2007; 67: 123-134.
17. Martinez-Cajas JL,Wainberg MA. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 2007; 76: 203-221.
18. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit. 2004; 26: 322-330.
19. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS. 1999; 13: 1623-1627.
20. Steiness E, Waldorf S, Hansen PB. Renal digoxin clearance: dependence on plasma digoxin and diuresis. Eur J Clin Pharmacol. 1982; 23: 151-154.
21. Troutman MD, Luo G, Gan LS, Thakker DR. The role of P-glycoprotein in drug disposition: significance to drug development. In: Rodrigues AD (ed). Drug-drug interactions. Drugs and the pharmaceutical sciences, Vol. 116. New York: Marcel Dekker; 2002. p. 295-357.
22. Van Asperen J, Van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res. 1998; 37: 429-435.
23. Varma MV, Perumal OP, Panchagnula R. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr Opin Chem Biol. 2006; 10: 367-373.
24. Witzke O, Plentz A, Schäfers RF, Reinhardt W, Heemann U, Philipp T. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function. AIDS. 1997; 11: 836-838.
25. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004; 53: 4-9.